Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kiromic BioPharma ( KRBP ) stock is taking off on SRA news. This has it planning to submit three new NDAs. These will focus on GDT allogeneic therapies. Source: Shutterstock Kiromic BioPharma (NASDAQ: ...
NEW YORK, June 07, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Kiromic BioPharma (NASDAQ: KRBP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Veru Inc. (NASDAQ: V...
I n Vivo Preclinical Data Expected to Enable Three New IND Applications to Evaluate Company’s Gamma Delta T cell Product Candidates Procel™, Isocel™, and Deltacel™ Kiromic BioPharma, Inc. (NASDAQ: KRBP) , a clinical-stage biotherapeuti...
Kiromic BioPharma press release (NASDAQ:KRBP): Q1 GAAP EPS of -$0.48. Cash and cash equivalents were $15,123,100 as of March 31, 2022, compared to $25,353,900 as of December 31, 2021. For further details see: Kiromic BioPharma GAAP EPS of -$0.48
Recent Corporate Highlights Include: New Leadership Appointed at the Company, Board of Director Level Completed Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell Platform Progressed a Master Cell Bank Strategy...
Kiromic BioPharma (NASDAQ:KRBP) has added ~21% in the pre-market Wednesday after the cancer-focused biotech announced its plans to submit an amended Investigational New Drug Application (IND) for its first oncology cell therapy candidate, Procel. The decision follows the clinic...
Company Provides Regulatory Update on Progress to Address Previously Outlined Chemistry, Manufacturing, and Control (CMC) Issues Related to Clinical Hold on Investigational New Drug Applications (INDs) A Type A FDA Meeting Will Not Be Pursued Company Announces Ongoing ...
Most people think of penny stocks as shares of companies trading for pennies. The standard definition considers these as stocks under $5, but you can’t argue with popular opinion. The exciting part about penny stocks under $1 is the volatility and gain potential they hold. Ca...
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”) , a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI ® (artificial intelligence) and big data mining platform to discover, validate an...
Kiromic BioPharma press release (NASDAQ:KRBP): FY GAAP EPS of -$2.26. Cash and equivalents were $25.35M as of December 31, 2021, compared to $10.15M as of December 31, 2020. For further details see: Kiromic BioPharma GAAP EPS of -$2.26
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...